Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2010 October;58(5) > Minerva Cardioangiologica 2010 October;58(5):599-610

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

REVIEWS  INTENSIVE CARDIAC CARE - PART II


Minerva Cardioangiologica 2010 October;58(5):599-610

language: English

Nobori drug eluting stent system: clinical evidence update

Danzi G. B. 1, Chevalier B. 2, Ostojic M. 3, Hamilos M. 4, Wijns W. 5

1 Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy;
2 Institut Cardiovasculaire Paris Nord, Massy, France;
3 Clinical Centre of Serbia, Belgrade, Serbia;
4 University Hospital of Heraklion, Crete, Greece;
5 Cardiovascular Center, Aalst, Belgium


PDF  


Drug eluting stents (DES) have changed the landscape of interventional cardiology with their high efficacy in preventing restenosis. Several DES are available for clinical use with different drugs, polymers and platforms. The Nobori™ is a novel generation drug eluting stent. The drug, Biolimus A9™, a sirolimus analogue, is immersed in a biodegradable polymer which is applied solely to the abluminal surface of a flexible stainless steel stent platform. The drug-polymer matrix is designed to release the drug simultaneously with the polymer degradation in a process lasting between 6-9 months. The coating design along with the lipophilicity of the drug is expected to optimize drug distribution and to reduce its release into the peripheral circulation. The drug free luminal surface might reduce negative impact on endothelization observed with DES with circumferential coating and durable polymers. Nobori™ stent is extensively studied in the comprehensive NOBORI clinical program. This stent showed superiority versus Taxus Liberte stent for in-stent late loss at 9 months in NOBORI 1 study, similarity to Cypher stent in NOBORI CORE study and superior performance versus both Taxus and Cypher stent in the study indirectly assessing endothelial function at 6-9 months after stent implantation. The landmark of NOBORI trials is very low rate of late and very late stent thrombosis along with exceptionally low target lesion revascularization rate.

top of page

Publication History

Cite this article as

Corresponding author e-mail

gbdanzi@tin.it